webinar register page

Webinar banner
Can Cardiovascular Disease (CVD), the world’s leading chronic killer, be predicted, cured and ultimately prevented? – A Discussion with Dr. Joe Tunac and Arterez
Join me on July 27th for a discussion

Can Cardiovascular Disease (CVD), the world’s leading chronic killer, be predicted, cured and ultimately prevented? – A Discussion with Dr. Joe Tunac and Arterez

Dr. Josefino B. Tunac has identified the multi-factorial root causes of cardiovascular disease (CVD) and now proved they can be characterized, cured and ultimately prevented. Please join this important discussion with the Arterez team; Dr. Tunac, President & Chairman, Mr. Michael Brennan, Chief Executive Officer and Mr. Brett Homovec, Chief Financial Officer about an opportunity to support the team that is literally changing the rules for CVD that could save and improve millions of precious lives.

Cardiovascular Disease (CVD) is the world’s leading chronic killer impacting more than one-third of the world’s population. US direct and indirect healthcare costs due to CVD is expected to grow to an estimated $1.5 trillion by 2030. Among the top 150 developing nations worldwide, CVD is the leading health risk and cost.

Arterez, Inc. is a Michigan biosciences group led by Dr. J.B. Tunac that has discovered the upstream etiology of chronic vascular disease. The company has developed and tested 9 new chemical entities in 30+ combinations and has since developed its first fixed dose oral therapy, Embotricin™, that prevents formation of emboli (clots) via plaque regression and restoration of the endothelial glycocalyx, while also addressing inflammation and oxidation, enabling healing at the cellular level rather than targeting symptoms. The company has also developed a biomarker panel for treatment monitoring, known as GlycoCardia™ that can also be used as a diagnostic tool for disease identification, staging and classification. First in-human studies are expected to begin in 2023. More information available at www.Arterez.com.

Jul 27, 2021 11:00 AM in Eastern Time (US and Canada)

Webinar logo
* Required information


Michael Brennan
Chief Executive Officer @Arterez, Inc
Mike is a serial entrepreneur and business leader with a 30 year record of leading and advising start-up, growth ventures and turn-arounds including four start-ups he founded and grew nationally. Mike’s education and certifications include the University of Detroit Jesuit 1982, Western Michigan University Psychology and Business 1982-1985, University of Detroit Mercy Cad Design 1985-1986, University of Michigan Entrepreneurial Development 1999-2000 and The Science of Selling  1994, 98, 99.  Private and 501C3 boards and community work include Detroit-based start-up advisory, public speaking for students, tech-entrepreneurs, small businesses and non-profits.
Brett Homovec
Chief Financial Officer @Arterez, Inc
Brett has spent the last several years serving entrepreneurs and business owners with strategy and implementation of business development plans, corporate finance  and  capital raising activities and mergers and acquisition advisory services. Brett gained his Corporate Finance/Mergers and Acquisitions experience as a VP in the Investment Banking Group for Rodman & Renshaw in New York and Chicago, Senior Associate in the Dean Witter Reynolds Corp Finance Group and as an audit professional for Touche Ross & Co. in New York.  Brett graduated from Dartmouth College with a B.A. in Economics and received his MBA in Finance from New York University - Stern School of Business.
Dr. Josefino B. Tunac
President & Chairman @Arterez, Inc
Dr. Joe Tunac is a medical scientist specializing in the discovery and development of drugs. He studies the biochemistry and physiology of the human body and designs drugs to target dysfunctional  mechanisms.  He  obtained  his undergraduate degree  from  the  University  of  the Philippines then graduate studies at South Dakota State, Penn State and a doctorate degree at Rutgers University, NJ (at The Waksman Institute: known as the birthplace of antibiotics); Dr. Tunac discovered his first drug (Hydroheptin) at the Waksman Institute. This feat prompted Merck to hire Dr. Tunac as a senior scientist and became instrumental in the discovery and development of multi-billion dollar drugs, including antiparasitic agent (Avermectin, Ivomec® Heartgard ®); and antibacterial antibiotic (Primaxin®). Avermectin was awarded the 2015 Nobel Prize in medicine